The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial
Open accessAbstract
Importance: Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective: To test the hypothesis of noninferiority of 1 month of DAPT compared with standard 12 months of DAPT for a composite end point of cardiovascular and bleeding events. Design, Setting, and Participants: Multicenter, open-label, randomized clinical trial enrolling 3045 patients who underwent PCI at 90 hospitals in Japan from December 2015 through December 2017. Final 1-year clinical follow-up was completed in January 2019. Interventions: Patients were randomized either to 1 month of DAPT followed by clopidogrel monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522). Main Outcomes and Measures: The primary end point was a composite of cardiovascular death, myocardial infarction (MI), ischemic or hemorrhagic stroke, definite stent thrombosis, or major or minor bleeding at 12 months, with a relative noninferiority margin of 50%. The major secondary cardiovascular end point was a composite of cardiovascular death, MI, ischemic or hemorrhagic stroke, or definite stent thrombosis and the major secondary bleeding end point was major or minor bleeding. Results: Among 3045 patients randomized, 36 withdrew consent; of 3009 remaining, 2974 (99%) completed the trial. One-month DAPT was both noninferior and superior to 12-month DAPT for the primary end point, occurring in 2.36% with 1-month DAPT and 3.70% with 12-month DAPT (absolute difference, -1.34% [95% CI, -2.57% to -0.11%]; hazard ratio [HR], 0.64 [95% CI, 0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority (P = .04). The major secondary cardiovascular end point occurred in 1.96% with 1-month DAPT and 2.51% with 12-month DAPT (absolute difference, -0.55% [95% CI, -1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for noninferiority (P = .005) but not for superiority (P = .34). The major secondary bleeding end point occurred in 0.41% with 1-month DAPT and 1.54% with 12-month DAPT (absolute difference, -1.13% [95% CI, -1.84% to -0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004 for superiority). Conclusions and Relevance: Among patients undergoing PCI, 1 month of DAPT followed by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel, resulted in a significantly lower rate of a composite of cardiovascular and bleeding events, meeting criteria for both noninferiority and superiority. These findings suggest that a shorter duration of DAPT may provide benefit, although given study limitations, additional research is needed in other populations. Trial Registration: ClinicalTrials.gov Identifier: NCT02619760.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Serruys, P. W., Morice, M.-C., Kappetein, A. P., Colombo, A., Holmes, D. R., Mack, M. J., Ståhle, E., Feldman, T. E., van den Brand, M., Bass, E. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804626 · Cited by 4,331
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J.-P., Costa, F., Jeppsson, A., Jüni, P., Kastrati, A., Kolh, P., Mauri, L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx419 · Cited by 2,987
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease.
Sianos, G., Morel, M., Kappetein, A. P., Morice, M., Colombo, A., Dawkins, K. D., van den Brand, M., Dyck, N. V., Russell, M. E., Mohr, F. W., et al. (2005) · PubMed · Cited by 2,293
Schömig, A., Neumann, F.-J., Kastrati, A., Schühlen, H., Blasini, R., Hadamitzky, M., Walter, H., Zitzmann-Roth, E.-M., Richardt, G., Alt, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604253341702 · Cited by 2,028
Long-term use of ticagrelor in patients with prior myocardial infarction
Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500857 · Cited by 1,999
Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409312 · Cited by 1,928
A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting
Leon, M. B., Baim, D. S., Popma, J. J., Gordon, P. C., Cutlip, D. E., Ho, K. K. L., Giambartolomei, A., Diver, D. J., Lasorda, D. M., Williams, D. O., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812033392303 · Cited by 1,815
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000404 · Cited by 1,355
Garcia-Garcia, H. M., McFadden, E. P., Farb, A., Mehran, R., Stone, G. W., Spertus, J., Onuma, Y., Morel, M.-A., van Es, G.-A., Zuckerman, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029289 · Cited by 990
Rao, A. K., Pratt, C., Berke, A., Jaffe, A., Ockene, I., Schreiber, T. L., Bell, W. R., Knatterud, G., Robertson, T. L., & Terrin, M. L. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90158-1 · Cited by 979
Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk
Urban, P., Meredith, I. T., Abizaid, A., Pocock, S. J., Carrié, D., Naber, C., Lipiecki, J., Richardt, G., Iñiguez, A., Brunel, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503943 · Cited by 818
Vranckx, P., Valgimigli, M., Jüni, P., Hamm, C., Steg, P. G., Heg, D., van Es, G. A., McFadden, E. P., Onuma, Y., van Meijeren, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31858-0 · Cited by 791
Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease
Park, S.-J., Kim, Y.-H., Park, D.-W., Yun, S.-C., Ahn, J.-M., Song, H. G., Lee, J.-Y., Kim, W.-J., Kang, S.-J., Lee, S.-W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100452 · Cited by 680
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents
Baber, U., Mehran, R., Giustino, G., Cohen, D. J., Henry, T. D., Sartori, S., Ariti, C., Litherland, C., Dangas, G., Gibson, C. M., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.064 · Cited by 556
Long-Term Safety of Drug-Eluting and Bare-Metal Stents
Palmerini, T., Benedetto, U., Biondi-Zoccai, G., Della Riva, D., Bacchi-Reggiani, L., Smits, P. C., Vlachojannis, G. J., Jensen, L. O., Christiansen, E. H., Berencsi, K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.017 · Cited by 470
Généreux, P., Giustino, G., Witzenbichler, B., Weisz, G., Stuckey, T. D., Rinaldi, M. J., Neumann, F.-J., Metzger, D. C., Henry, T. D., Cox, D. A., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1323 · Cited by 454
Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., Riva, D. D., Biondi-Zoccai, G., Feres, F., Abizaid, A., Hong, M.-K., Kim, B.-K., Jang, Y., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60263-x · Cited by 396
Räber, L., Magro, M., Stefanini, G. G., Kalesan, B., van Domburg, R. T., Onuma, Y., Wenaweser, P., Daemen, J., Meier, B., Jüni, P., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.058560 · Cited by 374
Valgimigli, M., Costa, F., Lokhnygina, Y., Clare, R. M., Wallentin, L., Moliterno, D. J., Armstrong, P. W., White, H. D., Held, C., Aylward, P. E., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw525 · Cited by 330
Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032615 · Cited by 243
Self-citationAspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 214
Self-citationNatsuaki, M., Morimoto, T., Yamaji, K., Watanabe, H., Yoshikawa, Y., Shiomi, H., Nakagawa, Y., Furukawa, Y., Kadota, K., Ando, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008708 · Cited by 195
Self-citationNatsuaki, M., Morimoto, T., Yamamoto, E., Shiomi, H., Furukawa, Y., Abe, M., Nakao, K., Ishikawa, T., Kawai, K., Yunoki, K., et al. (2015) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-015-0366-9 · Cited by 79
Self-citationToyota, T., Shiomi, H., Morimoto, T., Natsuaki, M., & Kimura, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174502 · Cited by 33
Self-citationOnuma, Y., Kimura, T., Räber, L., Magro, M., Girasis, C., van Domburg, R., Windecker, S., Mitsudo, K., & Serruys, P. W. J. C. (2015) · EuroIntervention · doi:10.4244/eijy14m06_09 · Cited by 29
Self-citation
Cited by
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization
Lawton, J. S., Tamis-Holland, J. E., Bangalore, S., Bates, E. R., Beckie, T. M., Bischoff, J. M., Bittl, J. A., Cohen, M. G., DiMaio, J. M., Don, C. W., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.006 · Cited by 1,558
Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., Abdelhamid, M., Barbato, E., De Hert, S., de Laval, I., Geisler, T., Hinterbuchner, L., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac270 · Cited by 1,141
Metadata
- Authors
- Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., Ohya, M., Suwa, S., Takagi, K., Nanasato, M., Hata, Y., Yagi, M., Suematsu, N., Yokomatsu, T., Takamisawa, I., Doi, M., Noda, T., Okayama, H., Seino, Y., Tada, T., Sakamoto, H., Hibi, K., Abe, M., Kawai, K., Nakao, K., Ando, K., Tanabe, K., Ikari, Y., Hanaoka, K. I., Morino, Y., Kozuma, K., Kadota, K., Furukawa, Y., Nakagawa, Y., Kimura, T., & for the STOPDAPT-2 Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-06-25
- Volume
- 321
- Issue
- 24
- Pages
- 2414
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2953479758
- Cited by
- 857
- References
- 38
- FWCI
- 82.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.